INTRODUCING YCANTH® access made easy

A non-dispensing pharmacy that simplifies the prescribing process by matching an in-network dispensing pharmacy to your patient's health care coverage

YCANTH Rx

Choose YcanthRx in your EMR

To ePrescribe

Find YcanthRx In the pharmacy search of your EMR:

YcanthRx 6 South 2nd Street Hamilton, OH 45011
NCPDP: 3689568 Phone: (855) 403-2364 Fax: (650) 332-8352

YCANTH is a specialty pharmacy medication.
Patient-labeled YCANTH ships directly to your office, clinic or hospital for administration.


Call YcanthRx

How to Load Your EMR

YCANTH® Prescribing Information

NDC 71349-070-01
Days Supply 21
Indication YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older
Dosage Form Topical Application
Prescription Form Topical solution 0.7%: Each mL of YCANTH contains 7 mg (0.7%) of cantharidin in a light violet to dark purple, slightly viscous liquid
SIG Apply topically to affected area every 3 weeks as needed
Dispense Quantity 1 or 2 (Single Use Applicators)
Dispense Unit EA
Specialty Pharmacy (In EHR, search by Zip code and in “ALL Pharmacies” database) YcanthRx
6 South 2nd Street
Hamilton, OH 45011
Notes to Pharmacy*
  • Patient’s PBM and Medical Insurance Carrier Names and Member ID#s
  • Previously Tried/Failed Treatments if applicable
  • Misc. Pertinent Clinical Information
Important Information to include on Prescription
  • Patient/Caregiver Phone # and Address
  • Diagnosis Code (ICD-10: B08.1)

* Important note: Send Patient Insurance and Clinical Information to YcanthRx with eRx via e-fax or other applicable method within EHR to expedite Prior Authorization process

Download eRx Instructions

YCANTH Application Training

YCANTH should be administered by a trained healthcare provider.

Review the applicator best practices before treating with YCANTH.

Go to YCANTH Virtual Training Go to Applicator Best Practices

About YcanthRx

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.

INDICATION

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
  • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
  • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE:

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.